Browsing by Author Cummins, Michelle

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 7 of 7
Issue DateTitleAuthor(s)Citation
2002Antisense co-suppression of Galphaq & Galpha11 demonstrates that both isoforms mediate M3-receptor-activated Ca2+ signalling in intact epithelial cellsBarden, Julian; Cook, David; Cummins, Michelle; O'Mullane, Lauren; Poronnik, Philip; School of Medical Sciences: Anatomy & Histology; School of Medical Sciences: Physiology; School of Public Health: NH&MRC Clinical Trials Centre; School of Medical Sciences: Physiology; Medicine Faculty OfficeAntisense co-suppression of Galphaq & Galpha11 demonstrates that both isoforms mediate M3-receptor-activated Ca2+ signalling in intact epithelial cells, Pfluegers Archiv: European journal of physiology, vol.444, 5,pp 644-653
2010Capecitabine, Bevacizumab and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized, Phase III MAX Study.Gebski, Val; Simes, Robert John; Stockler, Martin; Zannino, Diana; Ackland, Stephen P.; Broad, Adam; Chua, Yu Jo; Cummins, Michelle; Cunningham, David; Forgeson, Garry; Ganju, Vinod; Price, Timothy; Robinson, Bridget; Saunders, M; Tebbutt, Niall C; van Hazel, Guy; Wilson, Kate; Zalcberg, J; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreCapecitabine, Bevacizumab and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized, Phase III MAX Study., Journal of Clinical Oncology (Online), vol.28, 19,pp 3191-3198
2011Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal CancerCummins, Michelle; Lee, Chee; Chua, Ann; Hardingham, Jennifer; Murone, Carmel; Price, Timothy; Shivasami, Aravind; Tebbutt, Niall C; Townsend, Amanda; Weikhardt, Andrew; Wrin, Joseph; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreImpact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer, Journal of Clinical Oncology, vol.29, 19, 2011,pp 2675-2682
2010Negative regulation of Ca2+ influx during P2Y2 purinergic receptor activation is mediated by Gβγ-subunitsCampbell, Craig; Cook, David; Cummins, Michelle; Dinudom, Anuwat; Hosoda, Yutaka; Hu, Haibi; O'Mullane, Lauren; Poronnik, Philip; School of Medical Sciences: Physiology; School of Medical Sciences: Physiology; School of Public Health: NH&MRC Clinical Trials Centre; School of Medical Sciences: Physiology; School of Medical Sciences: Physiology; Biological Sciences; School of Medical Sciences: PhysiologyNegative regulation of Ca2+ influx during P2Y2 purinergic receptor activation is mediated by Gβγ-subunits, Cell Calcium, vol.47, 1, 2010,pp 55-64
2010Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trialCummins, Michelle; Gebski, Val; Sourjina, Tatiana; Stockler, Martin; Ganju, Vinod; Gibbs, David; Strickland, A. H.; Tebbutt, Niall C; van Hazel, Guy; Zalcberg, John; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreRandomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial, British Journal of Cancer, vol.102, 3,pp 475-481
2011Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumabCummins, Michelle; Marx, Gavin; Shannon, Jenny; Simes, Robert John; Wilson, Kate; Zannino, Diana; Abdi, Ehtesham A; Blum, R; Chantrill, L; Goldstein, D; Karapetis, Christos; Lowenthal, Raymond M.; Murphy, F; Nayagam, S; Price, Timothy; Strickland, A. H.; Tebbutt, Niall C; School of Public Health: NH&MRC Clinical Trials Centre; Medicine; Nepean Clinical School: Medicine; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreRisk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab, Annals of Oncology, vol.22, 8, 2011,pp 1834-1838
2015Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancerByth Wilson, Karen; Cummins, Michelle; Lee, Chee Khoon; Simes, Robert John; Asadi, K; Chionh, F; Mariadason, John M; Murone, C; Nagtegaal, ID; Price, Timothy; Punt, Cornelis JA; Scott, Andrew M; Tebbutt, Niall; Weickhardt, Andrew J; Williams, DS; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreVascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer, British Journal of Cancer, vol.113, 1, 2015,pp 37-45